Literature DB >> 19217726

Therapeutic management of patent ductus arteriosus.

Arpitha Chiruvolu1, Mambarath A Jaleel.   

Abstract

Management of patent ductus arteriosus (PDA) in premature neonates has always been a challenge to the neonatologist and continues to be a controversial topic. Indications for treatment are not clear. Approximately 40% of ductus arteriosus close spontaneously even in extremely-low-birth-weight neonates. Prophylactic or early pre-symptomatic treatment may unnecessarily expose these babies, in whom the ductus might close spontaneously, to pharmacologic agents and their adverse effects. On the other hand, with advancing postnatal age, delaying treatment could potentially decrease successful medical closure thereby increasing the rate of surgical ligation and the complications associated with surgery. We tried to develop some clinical guidelines for management of PDA in premature neonates based on evidence, or lack thereof, and experience.

Entities:  

Mesh:

Year:  2009        PMID: 19217726     DOI: 10.1016/j.earlhumdev.2008.12.007

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  3 in total

1.  Early NT-proBNP is able to predict spontaneous closure of patent ductus arteriosus in preterm neonates, but not the need of its treatment.

Authors:  D Martinovici; S Vanden Eijnden; P Unger; B Najem; B Gulbis; Y Maréchal
Journal:  Pediatr Cardiol       Date:  2011-06-09       Impact factor: 1.655

2.  Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation.

Authors:  Ozmert M A Ozdemir; Mustafa Doğan; Kazım Küçüktaşçı; Hacer Ergin; Ozlem Sahin
Journal:  Pediatr Cardiol       Date:  2013-08-13       Impact factor: 1.655

Review 3.  Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?

Authors:  Vassilios Fanos; Michele Pusceddu; Angelica Dessì; Maria Antonietta Marcialis
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.